Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT01494688 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01494688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01494688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2011
Completion date
February 7, 2018
Enrollment
217 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors